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Abstract
Background: The hypothesis of immunosurveillance suggests that new neoplasms arise very
frequently, but most are destroyed almost at their inception by an immune response. Its
correctness has been debated for many years.
In its support, it has been shown that the incidences of many tumor types, though apparently not
all, tend to be increased in immunodeficient animals or humans, but this observation does not end
the debate.
Alternative model: There is an alternative to the surveillance hypothesis; numerous studies have
shown that the effect of an immune reaction on a tumor is biphasic. For each tumor, there is some
quantitatively low level of immune reaction that, relative to no reaction, is facilitating, perhaps even
necessary for the tumor's growth in vivo. The optimum level of this facilitating reaction may often
be less than the level of immunity that the tumor might engender in a normal subject.
Conclusion:  The failure of a tumor to grow as well i n  t h e  n o r m a l  a s  i t  d o e s  i n  t h e
immunosuppressed host is probably not caused by a lack of tumor-cell killing in the suppressed
host. Instead, the higher level of immune response in a normal animal, even if it does not rise to
tumor-inhibitory levels, probably gives less positive support to tumor growth. This seems more than
a semantic distinction.
Introduction
It is now almost 50 years since the first convincing dem-
onstration that implantation of most MCA (3-methylcho-
lanthrene)-induced mouse sarcomas into animals of the
same inbred strain as the animal of origin could induce a
tumor-specific, growth-inhibiting immunity [1]. The phe-
nomenon proved general; tumors that were induced by
other known oncogens, such as other chemical carcino-
gens, radiation or oncogenic viruses, were usually demon-
strably immunogenic in transplantation tests. It was also
observed that, at least in the case of MCA-in-paraffin-
induced tumors, the degree of immunogenicity tended to
be directly related to the concentration of the inducer [2-
4], suggesting that sporadic, spontaneous tumors might
characteristically have little or perhaps no immunogenic-
ity. This point will be further discussed.
When immunogenic MCA -induced tumors were pas-
saged by transplantation through syngeneic hosts, the
immunogenicity proved to be surprisingly stable from
one tumor generation to the next [5]. Although both Bar-
tlett [6] and Bubenik [7] demonstrated some selective
effects related to immunogenicity, highly immunogenic
tumors usually remained highly immunogenic and those
of lesser immunogenicity tended to remain as such. How-
ever, sometimes a tumor appeared to either gain or lose an
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aspect of immunogenicity; this could be either a change in
immunizing ability [8] or a change in susceptibility to the
effect of immunity on the tumor's growth [5]; gain or loss
in either of these parameters was often compensated by an
opposite change in the other [5]. Although the tumors
could change their immunogenic characteristics with
time, their surprising overall stability suggested that the
changelings had little selective advantage [5]. The expecta-
tion that passage would select for nonimmunogenic
tumor variants, predicted by the immunosurveillance
hypothesis, was at best only partially realized.
Almost a quarter of a century ago, a wide range of obser-
vations, including a possible benefit to the fetus of an
anti-fetal immune reaction, suggested that immunity
might sometimes serve to stimulate or facilitate rather
than inhibit tumor growth [9,10]. This hypothesis was
soon supported by experiment. It was shown that a syn-
geneic, immunogenic tumor-implant in a thymectomized
and irradiated mouse was stimulated to grow by mixing
the inoculum with a small proportion of specifically
immune, as compared with nonimmune, spleen cells.
However, larger proportions of the same immune-cell
population inhibited tumor growth [11]. Owing to the
radiation and thymectomy, this finding was believed to be
unaffected by the host's native immune mechanisms.
Thus, it was concluded that the immune response affected
the growth of syngeneic tumor implants in mice biphasi-
cally; a quantitatively small immune reaction would facil-
itate tumor growth, but a larger reaction would be
inhibitory. An apparently analogous phenomenon was
seen in vitro when tumor cells were exposed to varying
numbers of specifically immune lymphoctes [12]. This
putative relationship, as illustrated in a previous publica-
tion [13], is shown in Fig. 1.
Presumably an immune reaction must be of small magni-
tude before it becomes large. This presumption is sup-
ported by the observation that 5 days after implantation
of an immunogenic, MCA-induced tumor, peripheral
blood lymphocytes were stimulatory to tumor growth in
vitro, but by 12 days they had become inhibitory [14].
This result seems to challenge the surveillance hypothesis:
could there be surveillance of incipient tumors if incipient
immune reactions are weak and therefore in the tumor-
facilitating range? So does the surprising stability of tumor
immunogenicity on passage through numerous trans-
plant generations [5], discussed above.
The biphasic effect of immunity on tumor-induction by 
applied oncogens
The biphasic effect of the immune reaction on syngeneic
tumor-implants in mice does not necessarily indicate the
effect of immunity on primary, untransplanted tumors of
the type seen in the clinic, i.e. on untransplanted tumors
growing in their autochthonous hosts. It was soon appar-
ent that the mouse in which a tumor originated was
immunologically very different from an animal that
received a tumor as an implanted fragment. The original
tumor-bearer was not noticeably immunized by the pri-
mary  in situ tumor and could only be immunized by
repeated subsequent implantations of that same tumor
[15]. This was true even if the in situ tumor were subse-
quently shown, when transplanted to a naive animal, to be
highly immunogenic. Furthermore, a subsequent inocula-
tion of the same immunogenic tumor usually grew better
in the primary mouse than it did in mice that had not pre-
viously been exposed to the tumor but had received a
comparable amount of carcinogen [16,17]. The mecha-
nistic basis for the failure of the primary tumor-bearer to
develop tumor-inhibiting immunity remains uncertain,
but may well be caused by a partial T-cell tolerance [18]
and/or a weak tumor-facilitating immune reaction
induced by the manner of initial antigen-presentation.
Irrespective of the mechanism, the essential point is that
the primary tumor-bearer does not seem to develop a
tumor-inhibiting immune reaction, which would seem to
be necessary for surveillance. However, the question
remains: does the immune reaction actually facilitate the
growth of an in situ tumor in the autochthonous host?
Many experiments, albeit most from my own laboratory,
give strong evidence that the answer is yes.
The first experiment I have selected for discussion exam-
ined the effect of immunity on the behavior of primary,
untransplanted, in situ tumors in normally immunocom-
petent mice. Prehn and Bartlett [19] showed that when
sarcomas were induced subcutaneously by surgically-
implanted paraffin wafers impregnated with a uniform
concentration of MCA (3-methylcholanthrene), the 1 54
resulting sarcomas possessed a wide range of immuno-
Relationship between tumor stimulation or inhibition and the  relative quantity of the immune reactants Figure 1
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genicity levels as judged by the growth of implants of
these tumors in specifically immunized mice. Curiously,
these immunogenicity levels fell into two distinct clusters,
one of higher average immunogenicity and one of lower,
with relatively few intermediates. In the primary animals,
undisturbed sarcomas that were shown in subsequent
transplantation studies to be of intermediate immuno-
genicity grew significantly faster (had shorter latencies)
than tumors belonging to either the greater or the lesser
immunogenicity cluster. Apparently, immune selection
favored an intermediate level of immunogenicity. However,
the average latency of primary sarcomas in the more
highly immunogenic cluster was significantly less than the
average latency of those in the lower. In other words, the
highly immunogenic tumors tended, on average, to grow
significantly faster than the less immunogenic ones when
undisturbed in the original immunocompetent host, but
not as fast as those of intermediate immunogenicity [19].
As part of the same experiment, tumors originally induced
in immunologically-isolated intraperitoneal diffusion-
chambers also exhibited the same two immunogenicity
clusters, though the tumors in the higher cluster were sig-
nificantly more immunogenic than those in the higher
cluster from the subcutaneous induction study [19]. This
observation reinforced the interpretation of the previous
findings: among the tumors that were induced subcutane-
ously, the immune response had indeed reduced the higher
tumor-immunogenicities toward an optimum level for
growth. The optimum immunogenicity for facilitating
subcutaneous tumor growth was apparently intermediate
between the high and the low clusters.
These facts are consistent with the interpretation that, at
least in the system examined, a modest immune reaction
against primary undisturbed MCA-induced sarcomas
stimulated or facilitated the tumor's growth. A modest
level of immunogenicity was associated with the tumors
that had the shortest latencies; the tumors of least immu-
nogenicity had the longest latencies. These data do not fit
easily with the immunosurveillance hypothesis. "Immu-
noediting" seemingly took place [20], but it apparently
resulted in tumors that grew best in the presence of the
intermediate rather than the lowest level of immune
response. According to the immunosurveillance hypothe-
sis, the tumors of least immunogenicity would have been
expected to exhibit the shortest latencies [21].
A second experiment approached the same problem by
directly varying the immune capacities of the hosts rather
than by assessing the immunogenicities of the tumors.
This was done by restoring to varying extents the immune
capacities of mice that had been exposed to radiation and
thymectomy. The restoration was accomplished by inject-
ing different numbers of normal adult spleen cells intra-
peritoneally prior to the standard exposure to
subcutaneously placed MCA. Moderate restoration of the
suppressed immune capacity resulted in more tumors at a
given time-point than did either maximal or minimal res-
toration. Note that the moderate restoration, in all proba-
bility, provided an immune capacity less than that to be
found in a normal, fully immunocompetent animal [22].
Another experiment consistent with a biphasic immune
effect on the development of MCA-induced tumors dif-
fered in that one of the experimental variables was the car-
cinogen concentration. I have already cited work
indicating that the average immunogenicity of MCA-
induced tumors tends to be directly related to the MCA
concentration in the paraffin wafers. Marked differences
in susceptibility to MCA-induced sarcogenesis had also
been observed among various inbred strains of mice. L.
Prehn and E. Lawler took advantage of these observations
to show that the mouse strain most susceptible to onco-
genesis with a high concentration of MCA was least sus-
ceptible with a low one, and vice versa [23]! Furthermore,
with either concentration of MCA, the most susceptible
mouse strain was made more resistant to tumor induction
by immunosuppressive radiation, but the least susceptible
strain was made more susceptible [24]. Both these experi-
ments again suggest that the optimal immune response
for facilitating the growth of in situ autochthonous, MCA-
induced tumors was intermediate in magnitude between
the highest and the lowest; it was certainly not the lowest,
as the surveillance hypothesis predicts. (It must be noted
that these results were not confirmed by Bernfeld and
Homburger, probably owing to their use of MCA in liquid
oil rather than as a solid wafer in paraffin [25]. Stutman
found no obvious relationship between the dosage of
MCA when administered in oil and the magnitude of the
resulting tumor's immunogenicity [26]).
Mouse mammary tumors induced by the mouse mam-
mary tumor virus show little or no immunizing ability
when transplanted into mice carrying that virus. However,
mammary tumors induced by MCA are highly immuno-
genic. Martinez [27] showed that newborn thymectomy
lowered the incidence of virus-induced mammary tumors,
but Johnson [28] reported that early thymectomy acceler-
ated the appearance of chemically induced ones. Although
from different laboratories, these combined results again
suggest that immunosuppression, in this case by newborn
thymectomy, favors the growth of more highly immuno-
genic  in situ tumors while inhibiting the development of
tumors of lesser immunogenicity. Again, the optimal
immune capacity for tumor growth was apparently greater
than zero.
Thymectomy at 3 days of age, in contrast to thymectomy
either at birth or at 7 days, causes hyperplastic autoim-Theoretical Biology and Medical Modelling 2006, 3:6 http://www.tbiomed.com/content/3/1/6
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mune lesions and increases susceptibility to subsequent
chemical carcinogenesis [29]. This increase in susceptibil-
ity occurred only with low concentrations of MCA; with
higher concentrations, the 3-day thymectomy was inhibi-
tory. Again, the data suggest that an increased immune
capacity, as evidenced in this case by the autoimmune dis-
eases, facilitated growth of only the weakly immunogenic
tumors produced by a low concentration of chemical; the
highly immunogenic tumors, produced by higher concen-
trations of MCA, were relatively inhibited.
Outzen altered the immune capacities of mice by giving
varied dosages of irradiation [30]. He then transplanted
on to them syngeneic skin that had been exposed to a
moderate dosage of MCA. Papillomas appeared earlier
and most frequently in the skin grafts on those animals
that had been exposed to an intermediate dosage of radia-
tion. This experiment had the advantage that the host ani-
mals were not directly exposed to any possible
immunosuppressive effects of MCA, nor was the skin
exposed to radiation. Again, in this experiment, oncogen-
esis was best facilitated in animals that had a diminished
but still positive immune capacity.
Ryan et al. [31] showed that antibodies to skin could be
induced in mice by injecting skin; syngeneic skin pro-
duced low levels, but xenogeneic produced very high
ones. It was then shown that syngeneic injections, which
produced low levels of antibody, promoted the appearance
of papillomas in carcinogen treated skin, but xenogeneic
injections failed to do so.
Viral oncogenesis also seems to be subject to a biphasic
effect of immunity. Murasko and Prehn [32] varied the
immunizing dosage of inactivated Moloney murine
leukemia virus and studied the effect on the induction of
tumors by subsequent inoculation with a standard dosage
of active virus. Mice immunized with high dosages devel-
oped significantly fewer tumors than did non-immunized
controls, but those immunized with low dosages showed
a markedly increased  tumor incidence. This facilitated
growth was abolished by irradiation of the mice with 450
rads 24 hours prior to challenge with active virus.
More studies could be discussed, but I have cited enough
to establish that immune efficacy is biphasically related to
deliberately induced, in situ, autochthonous tumors.
However, the biphasic curve is not merely a function of a
tumor response to varied levels of immunity; normal skin
allografts show a very similar phenomenon. Chai noted
the phenomenon when creating inbred strains of rabbit
[33]. During routine skin grafting he found that if two ani-
mals were genetically very similar, albeit not identical,
they might accept reciprocal skin grafts but nonetheless
mount a chronic inflammatory reaction that resulted in
the grafts developing a long lasting, chronic hyperplasia.
Thus, in rabbit skingrafts as in tumors, a mild immune-
reaction stimulated growth, but a larger reaction was
destructive.
The next question is, do all or most sporadic tumors have
sufficient immunogenicity to produce a similar biphasic
response curve?
A biphasic effect of immunity relative to spontaneous 
tumors?
Spontaneously arising rodent tumors, i.e. tumors that
arise without a known cause, seem at first glance to be
non-immunogenic as judged by the classical test for their
growth as implants in immunized, syngeneic hosts. Cer-
tainly the growth of challenge implants of these tumors is
not inhibited in putatively immunized hosts. However, in
the paper most often cited as demonstrating the non-
immunogenicity of spontaneous tumors [34], the authors
noted that, in seven out of seven cases, each using a differ-
ent spontaneous tumor, the challenge tumors in the puta-
tively immunized mice grew better than did the controls.
Since this work was done before the immunostimulation
theory had gained any traction, the authors dismissed the
result as some type of artifact. I believe it suggests that
even spontaneous tumors in the mouse usually cause,
when transplanted to immunologically competent ani-
mals, at least some small degree of immune reaction – not
a tumor-inhibitory reaction, but at least the tumor is
noticed by the immunological mechanism. An increased
incidence of various spontaneous tumors in immunode-
pressed animals also suggests that spontaneous tumors
usually have some immunogenicity [35].
The above observations, as well as the results already cited
in connection with the more immunogenic, deliberately-
induced tumors, suggest that a biphasic effect may be
expected. However, the difficulty of working with spo-
radic tumors renders conclusions weak and rather tenu-
ous.
If one is willing to call Kaposi's sarcoma a spontaneous
tumor, its incidence may be instructive. This tumor is a
common feature of the acquired immunodeficiency syn-
drome (AIDS), but it flares as recovery from immunosuppres-
sion occurs during effective AIDS treatment [36]. This
suggests that, although it grows best in the immunocom-
promised patient, Kaposi's sarcoma may not be caused by
decreased immunosurveillance, but rather by a reduction
in the HIV patient of the normal immune capacity to a
more optimal but still positive level for supporting tumor
growth. A reasonable interpretation is that this tumor
grows best when the immune capacity of the host is less
than normal, but not too low. As with any clinical observa-
tion, to an even greater degree than in mouse work, anyTheoretical Biology and Medical Modelling 2006, 3:6 http://www.tbiomed.com/content/3/1/6
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interpretation is merely the best bet among many known
and unknown possible confounders.
Consider what is probably the best known and one of the
earliest examples suggesting immunosurveillance: the
high incidence of some tumors, particularly skin tumors,
in patients with immunodeficiency induced to facilitate
kidney transplantation [37]. Assuming that immunosup-
pression is the proximal cause of the phenomenon, lack of
surveillance is the logical explanation for the data unless
one has in mind the probable biphasic nature of the
immune effect. However, if the effect of the immune reac-
tion on primary tumors is biphasic and if the optimum
level of host immune-capacity (for tumor growth) varies
not only from tumor to tumor but from one tumor type to
another, one need not invoke a tumor-inhibiting surveil-
lance. Let us assume, in the case of kidney transplant
patients, that the excess of skin tumors did indeed result
from the reduction of the normal immune capacity. The
elevated tumor incidence could be easily interpreted as
being caused, not by reduced surveillance, but by positive
stimulation by the residual immune reaction, now
reduced in such patients to a more nearly optimal level for
positive tumor-facilitation. This interpretation assumes
that had the immune capacities of the patients been still
further reduced, perhaps to nil, the incidence of skin
tumors would have again declined. Skin tumors may be
particularly facilitated by immunodeficiency because the
skin has an unusually active immune mechanism; such
tumors would, according to the facilitation hypothesis,
grow better if the unusually high immune reactivity were
reduced. Other tumor types, such as mammary cancers
and rectal carcinomas, usually find the reduced immune
capacity in the kidney-transplant patient to be even fur-
ther from their immunological needs than is the normal
immune capacity, probably because of a postulated lesser
innate tumor-immunogenicity and/or their arisal in a less
immunologically active site. Hence the lower  than
expected incidence of these tumors in immunocrippled
patients [38,39].
Oncogenesis in scid and nude mice and tests for 
surveillance
Many studies have been interpreted to support the immu-
nosurveillance idea. For example, Engel et al. [40] showed
that MCA-induced sarcomas that arose in immunocrip-
pled scid-mice grew poorly when transplanted to normal
syngeneic hosts as compared to tumors that had been
induced in immunocompetent hosts. They argued, quite
logically, that immunoselection had eliminated highly
immunogenic cells in the competent primary hosts (sur-
veillance) while such cells were allowed to persist in
tumors that arose in the crippled mice. However, these
data can be reinterpreted, as follows, to be compatible
with the data supporting the immunostimulation hypoth-
esis.
Remember that in the Prehn/Bartlett experiment there
was apparent selection toward a positive, optimal level of
immunogenicity (for tumor growth) [19]. In the Engel
experiment [40], selection in the immunocompetent pri-
mary hosts would presumably also have been toward an
optimal level, i.e. toward the level of immunogenicity best
for tumor growth in mice with that host's immune capac-
ity. Therefore, according to the facilitation interpretation,
the tumor cells from the competent hosts had been
selected for more optimal immunogenicity for tumor
growth in normal immunocompetent mice; selection in
the immunocrippled donors, on the other hand, was for
cells that would grow best when the immune reactivity
was lower. Thus, the tumor cells obtained from the immu-
nocompetent hosts exhibited better growth when cells of
each type were transplanted into immunocompetent
recipients. According to the facilitation hypothesis, the
selections were not dependent upon inhibiting or killing
the less well-adapted cells, but rather upon facilitating the
better adapted. This is, I think, more than a mere semantic
difference.
This interpretation of the Engel data [40] seems preferable
to the surveillance interpretation, not only because it
meshes with the data supporting the immunostimulation
hypothesis, but also because it offers an explanation for
an otherwise inexplicable observation that the authors
themselves noted; namely, that the tumors induced in the
crippled mice grew more slowly, when transplanted to
secondary crippled recipients, than did the tumors
obtained from the competent primary hosts [40]. The sur-
veillance interpretation offers no explanation for this; but
according to the immunostimulation interpretation,
tumors that originated in the immunocrippled scid mice,
because of the weakness of the immune response, would
have been subjected to little or no immunoselection for
faster growth and progression. In contrast, tumors that
had originated in immunocompetent hosts would have
undergone a selection for progression and increased
malignancy and so were better able to thrive when trans-
planted into the immunocrippled secondary hosts. (The
probable effect of immunity in promoting progression
will be discussed shortly).
A similar argument in favor of the facilitation hypothesis
can be made even if the immune crippling is quite severe.
Svane et al. [41] compared oncogenesis in nude mice with
that in normal immunocompetent mice. I suggest that the
excess susceptibility of the nudes could have been caused
by their low but still positive immune capacity being
somewhat nearer the optimum level for growth of these
highly immunogenic tumors, rather than by a lack of sur-Theoretical Biology and Medical Modelling 2006, 3:6 http://www.tbiomed.com/content/3/1/6
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veillance. Notwithstanding the general acceptance of
xenografts and the lack of detectable immunological
memory, highly immunogenic, and only highly immuno-
genic, tumor-implants grew significantly better in irradi-
ated than in non-irradiated nude mice, suggesting that
these mice retain a low but positive primary immune
capacity [42]. Thus, for some very immunogenic tumors,
the very low immune capacity of nude mice is apparently
greater than is optimal for their growth.
Although the immune capacity of the nudes in the Svane
experiment [41] was probably nearer the postulated opti-
mal level for growth of the tumors as compared to the nor-
mals, I suggest, because of the great immunogenicity of
the resulting tumors, that the immune capacity of the
nudes may actually have been less than optimum. Thus,
there may have been a selective pressure in favor of those
tumors that had a compensatingly greater immunogenic-
ity [42]. These considerations suggest, as is apparently true
for Kaposi's sarcoma, that a partial  restoration of the
immune system in the immunodeficient hosts might have
increased the tumor incidence.  Alternatively, a lower dos-
age of carcinogen might have had a similar effect [43].
On the other hand, the immune capacity of nudes was
indeed less than was optimal for MCA or dibenzanthrac-
ine-induced skin carcinogenesis; both Gershwin et al.
[44], and Outzen [[30], review] reported that papillomas
were induced more easily in normals or in immunologi-
cally restored nudes than they were in nudes. These find-
ings again suggest that the optimum immune capacity for
tumor support varies from one tumor type to another;
thus, human skin tumors apparently thrive at the lowered
levels of immune capacity found in the kidney-transplant
patient, while human mammary and rectal carcinomas
seem to grow relatively poorly if the immune capacity of
the patient is lowered [38,39].
It seems probable that any data that seem to show immu-
nosurveillance of primary in situ tumors can be reinter-
preted, by similar means, to be consistent with the
immunostimulation idea. To demonstrate immunosur-
veillance rigorously by an increased tumor incidence in
immunodepressed subjects, one must, I think, also show
that there would still be an increased tumor incidence if
the immune capacity of the host were further lowered,
perhaps all the way to nil. Without knowing where on Fig.
1 the data actually lie, interpretation is difficult.
There seem to be sufficient data to show clearly that highly
immunogenic tumors, given proper experimental param-
eters, can sometimes occur with greater speed and fre-
quency in immunodeficient subjects [37,41]. Recently,
data accumulated showing an increase of spontaneous
tumors in immunodeficient 129 mice lacking RAG2 and
or STAT1 [35]. This important result is rather surprising
inasmuch as past work has not suggested that spontane-
ous tumors would appear much more readily in immun-
odeficient than in normal mice [26]. Perhaps we need to
consider whether the higher tumor incidence was entirely
caused by the immune deficit. Most spontaneous tumors
are supposedly only weakly immunogenic. Thus, I would
have expected, according to the facilitation theory, that
the optimum host immune capacity for the growth of
such tumors might have been higher than probably
existed in the immunodeficient 129 mice. Would the inci-
dence of spontaneous tumors have been greater if the
immune deficit in the 129 mice been partially corrected?
Does immunity facilitate tumor progression?
That immunity may indeed promote dedifferentiation
and progression has been suggested by a number of obser-
vations. Progression is commonly observed when tumors
are transplanted serially in immunocompetent animals,
but seems to be much delayed or lacking in immunode-
prived hosts [45-47]. Some tumors may even become
more differentiated when passaged in athymic nude mice
[48]. Hammond passaged small-cell lung carcinomas
from inbred hamsters into animals of differing immune
capacities [49]. Since his important paper is difficult to
obtain, I shall quote his conclusions in full: "These studies
show a previously undescribed immune response-related modu-
lating influence upon classic tumor progression in vivo; the rate
and degree of dedifferentiation during tumor progression is
directly related to the level of host immunocompetence. Immu-
nodepression favors maintenance of the differentiated state, but
normal or elevated immunoreactivity is associated with progres-
sive dedifferentiation." More recently, de Visser et al. have
presented evidence for B-cell-dependent tumor progres-
sion [50] and Daniel et al. have shown that CD4+ T cells
can enhance skin cancer progression [51]. Much further
work will be necessary to confirm the effect of immunity
on tumor progression and to determine whether or not
such an effect is, like the effect on tumor growth, biphasic.
Mechanisms and philosophical considerations
Stutman [26], in a very comprehensive and heroic review
of studies on the carcinogenic effects of varying host
immune capacities, concluded that there was no net evi-
dence in favor of either immunostimulation or immuno-
surveillance. At the time of that review, it was probably
not realized that the effect of the immune response on
tumors is biphasic in such a way that an alteration in the
magnitude of the normal immune capacity could change
a less-than-optimal level of immunity (for tumor growth)
to a more-than-optimal or vice versa. Thus, in Fig. 1, mov-
ing the quantity of immune reactants from point b  to
point d or from point a to point e would have little effect
on tumor growth. Since both lower-than-optimal and
higher-than-optimal immune capacity levels might resultTheoretical Biology and Medical Modelling 2006, 3:6 http://www.tbiomed.com/content/3/1/6
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in much the same tumor incidence, little or no consistent
effect on tumor behavior might be seen in consequence of
changes in the immune capacities of the primary hosts.
The biphasic nature of the immune response in relation to
tumor growth would vastly complicate the interpretation
of most experiments and could help account for the lack
of overall effect noted by Stutman [26].
What could account for the evolution of an immune sys-
tem that, at moderate or low levels of reaction, apparently
promotes the growth of primary in situ tumors? It is logi-
cal to speculate that the vertebrate immune system was
selected, in part, by invading viruses, bacteria and para-
sites for their own benefit, not for the benefit of the host.
Therefore the system was probably selected, at least ini-
tially, to be helpful and even stimulating to the foreign
invaders when these arrived in small numbers, but to
inhibit the invaders if and when the invasion became
larger and more life-threatening [52]; few infectious
invaders would be benefited by rapid death of the host. A
primary in situ tumor begins as a very small invader and is
perhaps seen initially by the immune mechanism much as
a tiny parasitical infection might be seen; thus, it may like-
wise be facilitated to grow, rather than be inhibited, by
whatever weak immune reaction may be produced.
Indeed, it has been shown that a very tiny tumor inocu-
lum may grow, even in a specifically immunized mouse,
when a larger tumor implant would be rejected, a phe-
nomenon known as sneaking through [53].
The cellular and molecular bases of the facilitation phe-
nomenon are indubitably complex. I am persuaded by the
arguments of Sonnenschein and Soto that proliferation is
the cellular default state [54]; therefore, the apparent facil-
itation of tumor growth and progression by immune reac-
tants must, in actuality, be caused by interference with
normal, presumably non-immunological, inhibitors of
tissue and tumor growth. There are many data, as dis-
cussed by Osgood [55], to the effect that the less differen-
tiated cells in any organ or lesion are regulated by their
more differentiated progeny. There followed the concept
of the chalone, which actively inhibits the less differenti-
ated cells and is produced by the more differentiated [56].
A relative loss of the more differentiated tumor cells is a
critical part of histological tumor-grading. Since expan-
sion of any lesion seems to depend upon a lessening of
the inhibiting influence of the more differentiated cells, it
is evident that any mechanism that produces less differen-
tiation, or that interferes with signalling from the more
differentiated to the less differentiated, would promote
tumor-growth and progression. Perhaps, as a speculation,
the immune reaction is such a mechanism.
Tumor facilitation can apparently be mediated by any of
a large number of immune mediators including antibody
[31], T cells and their cytokines [57], macrophages [58]
and NK cells [59]. Epidermal growth factor has been
shown to stimulate tumor growth at picomolar concentra-
tions but to cause inhibition at nanomolar [60]. There has
been much recent interest in the role of inflammation in
promoting oncogenesis [61]; and as I have already men-
tioned, the inflammation associated with a mildly dispa-
rate skin-allograft can produce chronic hyperplasia in the
graft [33].
Conclusion
In view of the biphasic curve, it seems that the hypothesis
of immunosurveillance, at least as originally conceived,
must be discarded. The demonstration of an increased
tumor incidence after some degree, even a severe degree,
of immunosuppression cannot prove that there might not
have been a lower rather than a higher tumor incidence
had the immunosuppression been more complete. The
reality of the biphasic curve suggests the possibility, even
probability, that some level of immune reaction may be
necessary for tumor growth in vivo. At least this hypothe-
sis cannot, I believe, be excluded by any presently availa-
ble data.
Even if a facilitation phenomenon might initially be nec-
essary for the growth of in situ tumors, the immune reac-
tion might develop sufficient strength during later phases
of tumor growth to become inhibitory. In this sense, the
two hypotheses, facilitation and surveillance, are not nec-
essarily mutually exclusive if temporally displaced. Could
actual toxicity to a tumor sometimes follow initial tumor-
facilitation? Probably not; the fact that even highly immu-
nogenic, MCA-induced mouse sarcomas are facilitated in
situ by the level of immunity they induce [19] suggests
that the eventual development of a higher tumor-inhibi-
tory level of immunity is, in the case of most tumors, very
unlikely.
For a rather different view of the role of immunity in can-
cer, see the review by Robert D. Schreiber [35].
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